MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:38Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Fluoroquinolones]]
			[[Category:Antibacterials]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #237

2026-05-23T04:04:21Z

parser-claude batch MedTemplate pre-fill, Top 300 #237

New page

{{MedTemplate
| generic = Moxifloxacin
| brand = Avelox (oral/IV brand discontinued US); Vigamox, Moxeza (ophthalmic)
| structure =
| classes = [[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]], [[:Category:Antibacterials|Antibacterial]]
| uses = <vote slug="cap-use">Community-acquired pneumonia</vote>, <vote slug="acute-bacterial-sinusitis-use">Acute bacterial sinusitis</vote>, <vote slug="copd-exacerbation-use">Acute bacterial exacerbation of COPD</vote>, <vote slug="complicated-ssti-use">Complicated skin and soft-tissue infections</vote>, <vote slug="intra-abdominal-infection-use">Intra-abdominal infections (anaerobic coverage)</vote>, <vote slug="bacterial-conjunctivitis-use">Bacterial conjunctivitis (topical)</vote>
| starting_dose = 400 mg PO/IV once daily
| preparations = 400 mg tablets; 400 mg/250 mL IV; 0.5% ophthalmic solution
| fda_max = 400 mg/d
| pill_id =
| routes = Oral, IV, topical ophthalmic
| onset = Hours
| duration = 24 hours
| halflife = ~12 hours<ref name="avelox-label">FDA Prescribing Information, Avelox (moxifloxacin HCl), Bayer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s065,021277s057lbl.pdf</ref>
| bioavailability = ~90% (oral; not affected by food but reduced by divalent cations)<ref name="avelox-label" />
| pregnancy = '''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity).{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin<ref name="avelox-label" />
| mechanism = <vote slug="moxifloxacin-mech-claim">Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and producing bactericidal effect; the 8-methoxy substitution improves activity against gram-positives and anaerobes relative to earlier fluoroquinolones, broadening coverage to include atypicals plus anaerobes for intra-abdominal use.</vote> Substantial QT-interval prolongation — the most QT-prolonging fluoroquinolone — limits use in patients on other QT-prolonging agents or with electrolyte abnormalities<ref name="avelox-label" />.
}}

== References ==
<references />

Moxifloxacin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #237